TScan Therapeutics (NASDAQ: TCRX) revises milestones in updated investor presentation

Rhea-AI Filing Summary

TScan Therapeutics, Inc. furnished an updated corporate presentation that it plans to use in meetings with investors, analysts, and other stakeholders. The presentation reflects revised development and operational milestones, including adjusted timelines for its solid tumor program, updates to its pipeline in both hematologic malignancies and solid tumors, and new information on its target discovery work in autoimmunity.

The presentation is attached as Exhibit 99.1 and is also being made available through the company’s investor relations website, although website materials are not incorporated by reference into this report. The materials are furnished under a regulation disclosure item and are not deemed filed for liability purposes under the securities laws.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001783328 0001783328 2025-09-09 2025-09-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 9, 2025

TSCAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40603		82-5282075
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

830 Winter Street, Waltham, Massachusetts		02451
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (857) 399-9500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trade Symbol(s)		Name of each exchange on which registered
Voting Common Stock, $0.0001 par value per share		TCRX		The Nasdaq Global Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 9, 2025, TScan Therapeutics, Inc. (the “Company”) made available an updated corporate presentation (the “Presentation”) that it intends to use in potential meetings with investors, analysts, and other stakeholders. The Presentation reflects revisions to the Company’s anticipated development and operational milestones, including adjusted timelines for its solid tumor program, updates to the Company’s pipeline for both the hematologic malignancies and solid tumor programs, and updates on its target discovery initiatives in autoimmunity. The stockholders and investors are encouraged to review the Presentation for additional details regarding the Company’s programs and updated expectations.

A copy of the Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Presentation will also be available in the investor relations section of the Company’s website at https://ir.tscan.com. Information contained on the Company’s website is not incorporated by reference into this Current Report on Form 8-K, and you should not consider any information on, or that can be accessed from, the Company’s website as part of this Current Report on Form 8-K.

The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit  No.		Description
99.1		Presentation, dated September 9, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				TScan Therapeutics, Inc.
Date: September 9, 2025				By:		/s/ Gavin MacBeath
						Gavin MacBeath
						Chief Executive Officer

FAQ

What did TScan Therapeutics (TCRX) disclose in this 8-K?

TScan Therapeutics furnished an updated corporate presentation that includes revised development and operational milestones, pipeline updates for hematologic malignancies and solid tumors, and information on target discovery initiatives in autoimmunity.

How did TScan change its development plans for solid tumor programs?

The company stated that the updated presentation reflects adjusted timelines for its solid tumor program, indicating changes to when it expects key development milestones for those therapies.

What parts of TScan Therapeutics’ pipeline are discussed in the new presentation?

The presentation includes updates to the company’s pipeline in hematologic malignancies and solid tumors, as well as updates on its target discovery initiatives in autoimmunity.

Where can investors find the updated TScan (TCRX) corporate presentation?

A copy of the updated presentation is attached as Exhibit 99.1 to the report and is also available in the investor relations section of TScan’s website at https://ir.tscan.com.

Is the updated TScan presentation considered filed with the SEC?

The company specified that the information under the disclosure item, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Does TScan plan to update the corporate presentation regularly?

TScan stated that it undertakes no obligation to update, supplement, or amend the material attached as Exhibit 99.1, except as may be expressly set forth by specific reference in a future filing.